Ovid Therapeutics names new CFO and CBO in leadership reshuffle
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
July 8, 2026 7:00 AM EDTKevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovids financial operations, following Jeffrey Ronas transition to an advisory roleEliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric... More
